# Petition for *Inter Partes* Review United States Patent No. 9,555,027

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Inter Partes Review of:	)
U.S. Patent No. 9,555,027	)
Issued: January 31, 2017	)
Application No.: 14/512,189	)
Filing Date: Oct. 10, 2014	)

### For: Pharmaceutical Composition

FILED VIA E2E

### PETITION FOR *INTER PARTES* REVIEW OF U.S. PATENT NO. 9,555,027

# TABLE OF CONTENTS

I.	Overview1			
II.	Identification of Claims Being Challenged (37 C.F.R. § 42.104(B))7			
III.	Overview of the '027 Patent			
	А. В.	Specification		
IV.	The Person of Ordinary Skill in the Art9			
V.	Claim Construction			
	А. В.	Applicable Law10Construction of Claim Terms101. "equivalent dissolution profile"112. "pregelatinized starch"12		
VI.	Back	ground and State of the Art13		
	A. B. C.	Formulation of Oral Preparations with Good Disintegration and Rapid Dissolution Was Well-Known in the Art		
VII.	Scope	e and Content of the Prior Art18		
	А. В. С.	Fujihara Disclosed Oral Preparations of Lurasidone Including Disintegrants		
		Dosages		

i

	D.	Chowdary Taught the Amount of Pregelatinized Starch to
		Include in a Formulation to Obtain Rapid Dissolution and
		Disintegration
VIII.	Clain	ns 1-34 Would Have Been Obvious Over the Prior Art24
	A.	Ground 1: Claims 1-34 Would Have Been Obvious Over
		Fujihara in View of Aulton
		1. One of Ordinary Skill Would Have Been Motivated to
		Use the Lurasidone Oral Preparations of Fujihara
		2. Fujihara Discloses Ranges of Lurasidone Content and
		Excipients that Overlap with the Challenged Claims
		3. One of Skill Was Motivated to Select a Known
		Disintegrant in Fujihara
		4. It Would Have Been Obvious to Combine Fujihara With
		Aulton to Select Pregelatinized Starch as the Disintegrant
		Because It Was in a Small Group of Commonly-Used
		Disintegrants
		5. There Is No Evidence of Unexpected Results from the
		Claimed Ranges of Lurasidone or Pregelatinized Starch33
		6. Fujihara and Aulton Render Obvious Every Limitation of
		the Claims
	B.	Ground 2: Claims 1-34 Would Have Been Obvious Over
		Fujihara in View of Denton and Chowdary47
		1. One of Ordinary Skill Would Have Been Motivated to
		Use the Lurasidone Oral Preparations of Fujihara48
		2. Denton Disclosed the Use of Pregelatinized Starch in
		Oral Preparations to Produce Higher Dosages, Maintain
		Acceptable Tablet Size, and Obtain Equivalent
		Dissolution Profiles Across Dosages
		3. Chowdary Disclosed the Preferred Range of 10%-20%
		Pregelatinized Starch
		4. Fujihara, Denton, and Chowdary Render Obvious Every
		Limitation of the Claims51
	C.	There Was a Reasonable Expectation of Success in Formulating
		Pregelatinized Starch with Lurasidone
		1. Sumitomo Incorrectly Asserted that Highly Relevant Art
		Should Be Disregarded58

DOCKET

ii

### Petition for *Inter Partes* Review United States Patent No. 9,555,027

	D.	<ol> <li>Sumitomo Incorrectly Asserted that Pregelatinized Starch Has an Unpredictable Effect on Dissolution</li> <li>The Prior Art Did Not Teach Away From the Claimed Range of Pregelatinized Starch</li> </ol>	
IX.	The C	Office Has Not Previously Considered Substantially the Same	
	Art, E	Evidence, or Arguments	66
X.	Secor	ndary Considerations Do Not Overcome the Strong Evidence of	
	Obvio	ousness	68
	A.	Commercial Success	69
	B.	Long-Felt But Unmet Need or Failure of Others	70
	C.	Industry Praise	70
	D.	Unexpected Results	70
XI.	Conc	lusion	71
XII.	Requi	irements for Petition for Inter partes Review	71
	A.	Grounds for Standing (37 C.F.R. § 42.104(a))	71
	B.	Notice of Real Party-in-Interest (37 C.F.R. § 42.8(b)(1))	71
	C.	Notice of Related Matters (37 C.F.R. § 42.8(b)(2))	71
	D.	Notice of Lead and Back-up Counsel and Service Information	72
	E.	Fee for Inter Partes Review	72
	F.	Proof of Service	72

DOCKET

# TABLE OF AUTHORITIES

## CASES

<i>10x Genomics v. Univ. of Chicago</i> , IPR2015-01157, Paper 14 (Nov. 16, 2015)
<i>Agrizap, Inc. v. Woodstream Corp.</i> , 520 F.3d 1337 (Fed. Cir. 2008)
Aventis Pharma S.A. v. Hospira, Inc., 743 F. Supp. 2d 305 (D. Del. 2010), <i>aff'd</i> , 675 F.3d 1324 (Fed. Cir. 2012)
Coalition for Affordable Drugs II LLC v. NPS Pharms., Inc., IPR2015-00990, Paper 28 (Oct. 23, 2015)
<i>In re Applied Materials, Inc.</i> , 692 F.3d 1289 (Fed. Cir. 2012)44
<i>In re Geisler</i> , 116 F.3d 1465 (Fed. Cir. 1997)44
<i>Kayak Software Corp. v. Int'l Bus. Machs. Corp.</i> , CBM2016-00075, Paper 16 (Dec. 15, 2016)
<i>KSR Int'l Co. v. Teleflex Inc.</i> , 550 U.S. 398 (2007)2
<i>Merck &amp; Cie v. Gnosis S.p.A.</i> , 808 F.3d 829 (Fed. Cir. 2015)
Merck & Co. v. Biocraft Labs., Inc., 874 F.2d 804 (Fed. Cir. 1989)
<i>Merck &amp; Co. v. Teva Pharms. USA, Inc.,</i> 395 F.3d 1364 (Fed. Cir. 2005)
<i>Microsoft Corp. v. Multi-Tech Sys., Inc.,</i> 357 F.3d 1340 (Fed. Cir. 2004)12

**A L A R M** Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

DOCKET

# DOCKET A L A R M



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

# **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

# **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

# API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

### LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

### FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

### E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.